US 12,419,977 B2
Radiopharmaceuticals
Simon Puttick, Sydney (AU); William Tieu, Sydney (AU); and Kevin Kuan, Sydney (AU)
Assigned to AdvanCell Isotopes Pty Limited, Sydney (AU)
Filed by AdvanCell Isotopes Pty Limited, Sydney (AU)
Filed on Nov. 14, 2024, as Appl. No. 18/947,606.
Application 18/947,606 is a continuation of application No. PCT/AU2023/050763, filed on Aug. 11, 2023.
Claims priority of application No. 2022902273 (AU), filed on Aug. 11, 2022; and application No. 2022902274 (AU), filed on Aug. 11, 2022.
Prior Publication US 2025/0064994 A1, Feb. 27, 2025
Int. Cl. A61K 51/04 (2006.01); C07B 59/00 (2006.01)
CPC A61K 51/0482 (2013.01) [C07B 59/002 (2013.01); A61K 2121/00 (2013.01); C07B 2200/05 (2013.01)] 29 Claims
 
1. A compound of Formula (II) having the following structure:

OG Complex Work Unit Chemistry
wherein the compound of Formula (II) is also referred to as (3S,7S,26R,29R,32R)-29-benzyl-32-(4-hydroxy-3-iodobenzyl)-5,13,20,28,31,34-hexaoxo-37-(4,7,10-tris (2-amino-2-oxoethyl)-1,4,7,10-tetraazacyclododecan-1-yl)-4,6, 12,21,27,30,33-heptaazaheptatriacontane-1,3,7,26,37-pentacarboxylic acid,
or a pharmaceutically acceptable salt or solvate, thereof;
where the compound of Formula (II) is complexed to 212Pb.